Last reviewed · How we verify
Moxifloxacin Ophthalmic
At a glance
| Generic name | Moxifloxacin Ophthalmic |
|---|---|
| Also known as | Molcin(R), Vigamox 0.5% |
| Sponsor | Federal University of São Paulo |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
- Conjunctivitis
- Decreased visual acuity
- Dry eye
- Keratitis
- Ocular discomfort
- Ocular hyperemia
- Ocular pain
- Ocular pruritus
- Subconjunctival hemorrhage
- Tearing
- Infection
- Rash
Key clinical trials
- IN PATIENTS WITH CORNEAL ABRASIONS TREATED WITH COLLAGEN CORNEAL SHIELDS IN THE EMERGENCY DEPARTMENT SETTING (NA)
- Intrastromal Moxifloxacin as an Adjunctive Therapy in Recalcitrant Bacterial Keratitis (NA)
- Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction (PHASE3)
- PRO-232 in Patients Subjected to Cataract Surgery (PHASE3)
- Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II (PHASE3)
- Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo. (PHASE1)
- Dropless Pars Plana Vitrectomy Study (PHASE4)
- Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Moxifloxacin Ophthalmic CI brief — competitive landscape report
- Moxifloxacin Ophthalmic updates RSS · CI watch RSS
- Federal University of São Paulo portfolio CI